Regulation of Compounding Pharmacies

Published Online: Tuesday, October 22, 2013
Follow Pharmacy_Times:
In this video, shot at the National Community Pharmacists Association 115th Annual Convention in Orlando, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists, discusses whether and how regulation of compounding pharmacies needs to change in the wake of the meningitis outbreak caused by tainted steroids produced by the New England Compounding Center.

Related Articles
Lipscomb University College of Pharmacy students recently began working in a new sterile compounding laboratory constructed partly in response to the fungal meningitis outbreak in 2012.
Compounding pharmacies across the nation face tighter regulations following the 2012 fungal meningitis outbreak from tainted drugs distributed by the New England Compounding Center.
Lisa Faast, PharmD, pharmacy business specialist and member of Pharmacy Development Services, talks about how pharmacists' awareness of sterile compounding procedures has changed since the 2012 meningitis outbreak.
Beneficiary Advisory Panel Decision Sets Stage for Continued Coverage; Final Decision Rests with TRICARE Management Activity Director
Latest Issues
$auto_registration$